In pharmacological mouse models of AD, CBD prevented Aβ-induced spatial learning deficits, reduced the Aβ-induced increase in IL-6 (Martín-Moreno et al., 2011), and attenuated Aβ-evoked neuroinflammation (Esposito et al., 2007) and this appeared to be mediated via PPARγ as well (Esposito et al., 2011). Here, PPARG is linked to Alzheimer disease.